Today: 28 February 2026
Subscribe
Browse Category

NYSE:NVO 3 November 2025 - 11 November 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera shares fell about 15% Monday after the company accepted Pfizer’s revised takeover offer, ending a bidding war with Novo Nordisk. Pfizer will pay $65.60 per share in cash plus up to $20.65 in contingent value rights. Novo withdrew its bid over the weekend. Metsera cited U.S. FTC antitrust concerns with Novo’s proposal.
10 November 2025
····
Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

U.S. stock futures rose Monday as Senate action fueled hopes for an end to the government shutdown, with Nvidia up 3% premarket. Pfizer won the $10 billion Metsera bid, sending Novo Nordisk shares higher in Copenhagen. Rumble agreed to buy Germany’s Northern Data in an all-stock deal, gaining access to 22,400 Nvidia GPUs. Tyson Foods raised its FY2026 revenue outlook as chicken sales offset beef weakness.
10 November 2025
····
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Pfizer will acquire obesity drug developer Metsera in a deal worth up to $10 billion, with a shareholder vote set for Nov. 13. Novo Nordisk shares rose after it exited the bidding. Norway’s $1.5 trillion sovereign wealth fund said it will abstain from voting on Novo’s new board at a meeting Nov. 14. Novo also signed a deal to distribute its semaglutide weight-loss shot in India under the brand Poviztra.
10 November 2025
··
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera agreed to Pfizer’s revised takeover offer worth up to $10 billion after Novo Nordisk withdrew from bidding. The deal values Metsera at $86.25 per share, including $65.60 in cash and up to $20.65 via a contingent value right. Metsera shareholders will vote on the merger November 13. Both companies expect a swift closing if approved.
8 November 2025
····
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Pfizer secured a deal to acquire obesity-drug developer Metsera for up to $10 billion after Novo Nordisk withdrew its rival bid, citing FTC antitrust concerns. Metsera shareholders are set to vote Nov. 13 on Pfizer’s offer of $65.60 in cash plus up to $20.65 per share in contingent value rights. Metsera’s board recommended approval. Metsera shares surged nearly 60% during the bidding.
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer will acquire Metsera for up to $10 billion after Metsera accepted a revised cash-and-CVR offer late Friday, ending Novo Nordisk’s competing bid. Metsera’s board cited U.S. antitrust risks with Novo’s proposal following FTC feedback. Pfizer will pay $65.60 per share plus a contingent value right of up to $20.65. A shareholder vote is set for Nov. 13, with closing expected soon after.
8 November 2025
···
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer agreed to acquire Metsera for up to $10 billion, outbidding Novo Nordisk and ending a heated takeover battle. Metsera shareholders will vote on the deal Nov. 13, with closing expected soon after pending approvals. Shares of MTSR surged to $83.18 following the announcement. Regulators are expected to review the deal’s impact on the obesity-drug market.
8 November 2025
·····
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Pfizer shares fell 2.3% to $24.28 amid heavy trading as a Delaware judge allowed Metsera to exit its deal with Pfizer, intensifying the takeover battle with Novo Nordisk. Pfizer is reportedly considering a higher bid ahead of Metsera’s Nov. 13 shareholder vote. The company marked its dividend record date today for a $0.43 payout. Earlier this week, Pfizer raised its 2025 EPS guidance after beating Q3 estimates.
7 November 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Novo Nordisk shares fell about 2–4% Friday after the company and Eli Lilly agreed to cut U.S. prices for GLP‑1 drugs, including Medicare coverage, reducing monthly costs to $149–$350. Novo expects a low single-digit hit to global sales growth in 2026. A Delaware court backed Novo’s bid for Metsera, while U.S. regulators flagged antitrust concerns. Novo missed Q3 estimates and lowered its full-year outlook.
7 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Novo Nordisk shares fell about 2.4% after the White House announced a deal with Novo and Eli Lilly to expand Medicare coverage and lower prices for anti-obesity drugs. The agreement includes a Medicare Part D pilot starting in 2026, lower prices in Medicare, Medicaid, and cash channels, and a three-year tariff exemption. Novo expects a low single-digit hit to 2026 global sales growth. NVO traded at $47.30 as of 12:51 p.m. ET.
6 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Novo Nordisk ADRs closed at $47.36, down from a $47.75 open, after news of a White House deal to cut GLP-1 drug prices and expand Medicare/Medicaid access. The company confirmed lower U.S. prices and a pilot for Medicare Part D obesity drug coverage. Novo is also in a $10 billion bidding war with Pfizer for obesity-drug maker Metsera. Volume topped 29 million shares.
6 November 2025
·
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

A Delaware court denied Pfizer’s request to block Metsera from ending their merger deal in favor of Novo Nordisk’s higher bid. Pfizer plans to raise its offer after Novo’s proposal reached up to $10 billion. FTC staff warned Novo’s bid structure could violate pre-merger rules. Pfizer shares traded near $24.61 midday Thursday.
6 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Novo Nordisk cut its 2025 sales and profit outlook for the fourth time this year after third-quarter results missed forecasts, with Wegovy revenues below expectations. Operating profit fell 30% due to restructuring costs. The company faces rising competition from Eli Lilly and U.S. copycat drugs, as well as mounting pricing pressure. Shares have dropped up to 50% in 2025; Novo plans 9,000 job cuts and a $10 billion bid for Metsera.
5 November 2025
···
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera shares jumped nearly 20% to $73.29 on November 4, 2025, hitting a 52-week high after Novo Nordisk raised its takeover offer to $86.20 per share, topping Pfizer’s $70 bid. Metsera’s board called Novo’s proposal “Superior.” A Delaware judge declined to halt the bidding war, fueling further gains. Pfizer has until midweek to counter Novo’s offer.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer shares traded near $24.60 on Nov. 4, 2025, down about 8–9% year-to-date and over 60% from their 2021 peak. Q3 adjusted earnings beat forecasts at $0.87 per share, but revenue missed slightly at $16.65 billion. Pfizer raised its full-year profit outlook and reaffirmed revenue guidance. The company is locked in a takeover battle with Novo Nordisk for obesity drug developer Metsera.
4 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer reported Q3 2025 adjusted earnings of $0.87 per share, beating estimates, with revenue at $16.65–$16.7 billion. The company raised its full-year profit outlook to $3.00–$3.15 EPS. Sales of COVID products plunged, but demand for Eliquis and Vyndaqel rose. Pfizer sued Novo Nordisk over a $7.3 billion bid for obesity drugmaker Metsera; a court hearing is set for Nov. 4.
4 November 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
1 … 3 4 5 6 7
Go toTop